- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| Mi | Longeveron beruft Teamarzt der St. Louis Cardinals in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| Mi | George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron Board of Directors | 1 | GlobeNewswire (USA) | ||
| 22.09. | Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa | 1 | GlobeNewswire (USA) | ||
| 19.09. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.09. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.09. | Longeveron appoints interim CEO | 2 | Seeking Alpha | ||
| 03.09. | Longeveron names Than Powell as interim CEO in leadership shuffle | 2 | Investing.com | ||
| 03.09. | Longeveron Announces Key Leadership Updates | 92 | GlobeNewswire (Europe) | Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa'el... ► Artikel lesen | |
| 18.08. | Roth slashes price target on Longeveron | 3 | Cantech Letter | ||
| 14.08. | Longeveron reports Q2 results | 3 | Seeking Alpha | ||
| 13.08. | Longeveron Inc. Q2 Loss Declines | 1 | RTTNews | ||
| 13.08. | Longeveron Announces Second Quarter 2025 Financial Results and Provides Business Update | 269 | GlobeNewswire (Europe) | Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS... ► Artikel lesen | |
| 13.08. | Longeveron Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Preview: Longeveron's Earnings | 1 | Benzinga.com | ||
| 11.08. | Longeveron closes $5 million public offering of common stock | 2 | Investing.com | ||
| 11.08. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.08. | Longeveron Announces Closing Of Up To $17.5 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 08.08. | Longeveron Announces Up To $17.5 Million Public Offering | 8 | GlobeNewswire (USA) | ||
| 08.08. | Longeveron Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,25 | +0,06 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
| CUREVAC | 4,562 | -0,70 % | CureVac mit EILMELDUNG: Könnte die Aktie jetzt komplett drehen - Experten empfehlen sofort zu handeln! | ||
| CRISPR THERAPEUTICS | 63,00 | +1,61 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress | ||
| OCUGEN | 1,589 | +6,11 % | Ocugen plant drei Zulassungsanträge für Gentherapien gegen Erblindung bis 2028 | ||
| EDITAS MEDICINE | 3,317 | +0,06 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| CYTODYN | 0,204 | 0,00 % | CytoDyn Inc.: September 2025 Letter to Shareholders | VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. ("CytoDyn" or the "Company"), I am pleased to share the... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,032 | -0,62 % | SOL Global Investments Corp.: SOL Global CEO Davide Marcotti Charts Strategic Growth Path with International Investor Outreach | Toronto, Ontario--(Newsfile Corp. - September 22, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") is pleased to provide an update under the... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,996 | -2,33 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| TRINITY BIOTECH | 1,070 | +2,88 % | TRINITY BIOTECH PLC - 6-K, Report of foreign issuer | ||
| ANAVEX LIFE SCIENCES | 8,158 | +4,86 % | Anavex Life Sciences Corp.: Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX3-71 Program | ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 21,920 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| CERUS | 1,278 | 0,00 % | Cerus Corporation: The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions | Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,270 | -9,29 % | Ovid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties | NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | Windtree Therapeutics: Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients | Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 1,260 | 0,00 % | Aptevo Therapeutics Inc. - S-1, General form for registration of securities |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,765 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.